Li Yaqi, Yang Dawei, Gao Xiwen, Ju Minjie, Fang Hao, Yan Zuoqin, Qu Huanru, Zhang Yuanhao, Xie Linshan, Weng Huifen, Bai Chunxue, Song Yuanlin, Sun Zhirong, Geng Wenye, Gao Xiang
Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China.
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Nutr Metab (Lond). 2022 Dec 28;19(1):84. doi: 10.1186/s12986-022-00717-w.
Evidence from previous studies has suggested that ginger extract exhibits the potential as an alternative treatment for Coronavirus disease 2019 (COVID-19). Here, we want to investigate whether ginger supplement improves the clinical manifestation of hospitalized COVID-19 individuals.
A total of 227 hospitalized individuals with COVID-19 were randomized to either the control (n = 132) or intervention group (n = 95). The intervention group took ginger supplement orally at the dosage of 1.5 g twice daily, until they were discharged from the hospital. Both groups received the same standard of general medical care during hospitalization, and the length of stay was recorded and compared between groups.
Among all participants, a significant reduction in hospitalization time (the difference between the treatment and control groups was 2.4 d, 95% CI 1.6-3.2) was detected in response to the ginger supplement. This effect was more pronounced in men, participants aged 60 years or older, and participants with pre-existing medical conditions, relative to their counterparts (P-interactions < 0.05 for all).
Ginger supplement significantly shortened the length of stay of hospitalized individuals with COVID-19.
The trial was registered on the Chinese Clinical Trial Registry (ChiCTR2200059824).
先前研究的证据表明，生姜提取物具有作为2019冠状病毒病（COVID-19）替代治疗方法的潜力。在此，我们想研究补充生姜是否能改善住院COVID-19患者的临床表现。
总共227名住院的COVID-19患者被随机分为对照组（n = 132）或干预组（n = 95）。干预组口服生姜补充剂，剂量为每日两次，每次1.5克，直至出院。两组在住院期间接受相同标准的常规医疗护理，并记录住院时间并在组间进行比较。
在所有参与者中，发现补充生姜后住院时间显著缩短（治疗组与对照组的差异为2.4天，95%置信区间为1.6 - 3.2）。相对于其对应人群，这种效果在男性、60岁及以上的参与者以及有基础疾病的参与者中更为明显（所有P交互作用均<0.05）。
补充生姜显著缩短了住院COVID-19患者的住院时间。
该试验在中国临床试验注册中心注册（ChiCTR2200059824）。
